Energy Bear 3X Direxion (ERY) 13.71 $ERY OPEC Output

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Energy Bear 3X Direxion (ERY) 13.71 $ERY

OPEC Output Freeze Speculation Lift Oil, Energy ETFs
editor@etftrends.com (ETF Trends) - ETF Trends - Mon Aug 08, 12:56PM CDT
Energy sector exchange traded funds surged alongside crude oil prices as the Organization of Petroleum Exporting Countries set plans for informal talks in September, fueling speculation that the oil cartel could execute an output freeze in light of...
USO: 10.53 (+0.13), ERY: 13.71 (-0.07), XES: 17.58 (+0.33), DDG: 25.74 (-0.45), DUG: 47.46 (-0.31), BNO: 13.99 (+0.17), PXJ: 10.73 (+0.23), PSCE: 17.31 (+0.29), DRIP: 22.89 (-0.70), XLE: 68.55 (+0.08)

ETF Ideas for Profiting From a Pullback In Oil Stocks
editor@etftrends.com (ETF Trends) - ETF Trends - Fri Aug 05, 7:39AM CDT
With oil prices faltering again, some active, risk-tolerant traders are looking for options to profit from a slide in energy equities. For now, the Energy Select Sector SPDR (NYSEArca: XLE), the largest equity-based energy exchange traded fund, has...
FENY: 19.18 (+0.06), VDE: 94.49 (+0.37), ERY: 13.71 (-0.07), DDG: 25.74 (-0.45), DUG: 47.46 (-0.31), IYE: 37.95 (+0.11), DRIP: 22.89 (-0.70), XLE: 68.55 (+0.08)

Oil in Bear Territory: Short Oil & Energy ETFs
Zacks Equity Research - Zacks Investment Research - Wed Aug 03, 9:56AM CDT
With bears flexing muscles in the oil patch, one can gain by shorting oil and energy ETFs.
USO: 10.53 (+0.13), ERY: 13.71 (-0.07), DDG: 25.74 (-0.45), DNO: 71.60 (-1.00), DUG: 47.46 (-0.31), BNO: 13.99 (+0.17), DWTI: 78.91 (-2.92), SCO: 89.37 (-2.18)

Energy ETFs Hit A Snag as Oil Prices Enter Bear Market
editor@etftrends.com (ETF Trends) - ETF Trends - Wed Aug 03, 9:36AM CDT
The third quarter is often unkind to the energy sector, a thesis that was proven accurate during a rough July for commodities, including oil prices. That theme is predictably weighing on equity-based energy exchange traded funds, such as the Energy...
FENY: 19.18 (+0.06), VDE: 94.49 (+0.37), ERY: 13.71 (-0.07), DDG: 25.74 (-0.45), DRIP: 22.89 (-0.70), XLE: 68.55 (+0.08)

Will New SEC Rules Hurt Triple Leveraged ETFs?
Sweta Killa - Zacks Investment Research - Thu Jun 09, 9:06AM CDT
The popularity of leveraged ETFs might fade in the coming months given that SEC is in the process of implementing some measures that would restrict the amount of funds that can be invested in these products.
UPRO: 74.52 (+1.32), ERY: 13.71 (-0.07), EDZ: 21.57 (-0.44), TNA: 82.25 (+3.47), SRTY: 17.24 (-0.83), FAS: 30.11 (+0.54), NUGT: 21.91 (-0.30), TQQQ: 130.01 (+2.97), LABD: 15.58 (-0.42)

Bears Look to Feast on These 8 Energy ETFs
etftrends@etftrends.com (ETF Trends) - ETF Trends - Tue May 10, 7:10AM CDT
Oil prices and energy stocks are rebounding this year, but big-name energy stocks and exchange traded funds (ETFs), such as the Energy Select Sector SPDR (NYSEArca: XLE) have been retreating in recent days, perhaps inviting once eager short sellers...
FENY: 19.18 (+0.06), VDE: 94.49 (+0.37), ERY: 13.71 (-0.07), DUG: 47.46 (-0.31), IYE: 37.95 (+0.11), DRIP: 22.89 (-0.70), XLE: 68.55 (+0.08)

The Zacks Analyst Blog Highlights: PowerShares DB Crude Oil Double Short ETN, VelocityShares 3x Inverse Crude ETN, ProShares Short Oil & Gas ETF, ProShares UltraShort Oil & Gas ETF and Direxion Daily Energy Bear 3x Shares ETF
Zacks Equity Research - Zacks Investment Research - Tue Apr 19, 8:30AM CDT
The Zacks Analyst Blog Highlights: PowerShares DB Crude Oil Double Short ETN, VelocityShares 3x Inverse Crude ETN, ProShares Short Oil & Gas ETF, ProShares UltraShort Oil & Gas ETF and Direxion Daily Energy Bear 3x Shares ETF
ERY: 13.71 (-0.07), DDG: 25.74 (-0.45), DTO: 133.52 (-1.70), DUG: 47.46 (-0.31), DWTI: 78.91 (-2.92)

How to Profit from the Failed Doha Meeting via ETFs
Zacks Equity Research - Zacks Investment Research - Mon Apr 18, 10:56AM CDT
With oil producers failing to clinch an output freeze deal in Doha, investors may consider shorting oil or the entire energy space via ETFs.
USO: 10.53 (+0.13), ERY: 13.71 (-0.07), DDG: 25.74 (-0.45), XOP: 37.16 (+0.34), DTO: 133.52 (-1.70), IPW: 17.18 (+0.28), DUG: 47.46 (-0.31), BNO: 13.99 (+0.17), IEO: 59.93 (+0.16), SCO: 89.37 (-2.18)

More Pain for Energy ETFs Post Exxon, Chevron Q4 Results
Sweta Killa - Zacks Investment Research - Wed Feb 03, 9:15AM CST
The lackluster results from Exxon and Chevron and their sliding share prices have further dragged down energy ETFs, which are already struggling with the collapse in oil prices.
FENY: 19.18 (+0.06), VDE: 94.49 (+0.37), ERY: 13.71 (-0.07), DDG: 25.74 (-0.45), DUG: 47.46 (-0.31), XOM: 83.54 (+0.24), CVX: 99.98 (+0.35), IYE: 37.95 (+0.11), XLE: 68.55 (+0.08)

The Zacks Analyst Blog Highlights: ProShares Short Oil & Gas, ProShares UltraShort Oil & Gas, Direxion Daily Energy Bear 3x Shares, Direxion Daily S&P Oil & Gas Exp. & Prod. Bear 3x Shares and ProShares UltraShort Oil & Gas Ex
A Clark - Zacks Investment Research - Tue Jan 19, 8:30AM CST
The Zacks Analyst Blog Highlights: ProShares Short Oil & Gas, ProShares UltraShort Oil & Gas, Direxion Daily Energy Bear 3x Shares, Direxion Daily S&P Oil & Gas Exp. & Prod. Bear 3x Shares and ProShares UltraShort Oil & Gas Exploration & Production
USO: 10.53 (+0.13), ERY: 13.71 (-0.07), SOP: 15.50 (unch), DDG: 25.74 (-0.45), DUG: 47.46 (-0.31), DRIP: 22.89 (-0.70)

Oil Hits 12-Year Low: Short Energy Stocks with ETFs
Sweta Killa - Zacks Investment Research - Mon Jan 18, 9:57AM CST
investors who are bearish on oil right now may want to consider a near-term short on the energy sector with these ETFs.
ERY: 13.71 (-0.07), SOP: 15.50 (unch), DDG: 25.74 (-0.45), DUG: 47.46 (-0.31), DRIP: 22.89 (-0.70)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Pan-Mass Challenge Gifts $80M to Dana-Farber for 2026

Updated Category News Views 135

A Momentous Gift in a Crunch Time for Cancer Research Biking and philanthropy might seem like an odd duo, but let me tell you, the Pan-Mass Challenge (PMC) is making that partnership look like peanut butter and jelly. This year, PMC rolled out a jaw-dropping $80 million gift to the Dana-Farber Cancer Institute. You heard right—eighty million smackeroos. Talk about going...

Continue Reading
Novo's CagriSema Trials Show Promising Weight Loss

Updated Category News Views 220

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

Continue Reading
Portillo's Faces Class Action: Investor Losses at Stake

Updated Category News Views 210

Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...

Continue Reading
InstaHeat 35K: FOGATTI Offers Upgraded RV Furnace Control

Updated Category News Views 318

Winter RV Trips Just Got Cozier There's nothing quite like hitting the open road in an RV during the winter months. But let's face it, nobody wants to return to a cabin that's as frigid as the great outdoors. Here's where FOGATTI steps up its game with the InstaHeat Ultra 35K RV Furnace. They’ve tinkered with the thermostat to iron out more precise control, just in time...

Continue Reading
Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Updated Category News Views 269

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...

Continue Reading
Uber Data Breach: Class Action Investigation Begins

Updated Category News Views 283

When Tech Meets Trouble: Uber's Data Breach Picture this: the hum of Uber rides weaving through your city, drivers none the wiser that personal info has been pried from the vaults thanks to their tech partner, Fireworks AI. Uber, folks, is in hot water once again. This isn’t just another tech hiccup; it's a legal whirlwind brewing up courtesy of Edelson Lechtzin LLP, a...

Continue Reading
WHO and RCSI Bahrain Join Forces on Health Initiatives

Updated Category News Views 406

Forging a Healthier Pathway In a world where healthcare challenges rise faster than my blood pressure during a stock market crash, the World Health Organization (WHO) and the Royal College of Surgeons in Ireland (RCSI) – Medical University of Bahrain have inked a deal to tackle these issues head-on. The memorandum of understanding (MoU) signed on November 15, 2026,...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 180

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
YONDELIS: Thai Approval Opens New Sarcoma Treatment Path

Updated Category News Views 103

New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...

Continue Reading
Investors Gear Up for Lennar Class Action Lawsuit

Updated Category News Views 235

High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...

Continue Reading

Top 5 Most Recently Viewed Articles

Kulicke & Soffa Announces Conference Call for Fiscal Results

Updated Category News Views 122

Kulicke & Soffa Schedules Conference Call Kulicke and Soffa Industries, Inc. (NASDAQ: KLIC), a leading name in semiconductor assembly technology, has announced a conference call to discuss its third fiscal quarter financial results and business outlook. The call is set for a future date, highlighting the company's commitment to transparency and communication with its...

Continue Reading
ARMOUR Residential REIT Launches Major Stock Offering for Growth

Updated Category News Views 162

ARMOUR Residential REIT Enters Public Stock Offering ARMOUR Residential REIT, Inc. (NYSE: ARR and ARR-PRC) has officially announced an underwritten public offering of 18,500,000 shares of common stock. The company is poised to grant underwriters an additional option to purchase up to 2,775,000 shares, making this a significant move for ARMOUR as it aims to enhance its...

Continue Reading
Celebrate Mother's Day with a Unique Brunch at Cannon + Belle

Updated Category News Views 195

Cannon + Belle Offers a Memorable Mother's Day Brunch Cannon + Belle at Hilton Austin is excited to announce an elevated Mother's Day brunch that promises to create unforgettable memories. This year, the restaurant will be hosting a special brunch event aimed at honoring mothers and all they do. With an impressive menu curated by the talented Chef Gereamy Cater, guests...

Continue Reading
Figma's Shares Surge in IPO But Valuation Remains a Concern

Updated Category News Views 244

Figma's Impressive IPO Performance Figma Inc. (NYSE: FIG) has captured significant investor attention following its explosive debut in the stock market. After launching its initial public offering, the company's shares skyrocketed by over 250%, marking a remarkable milestone for the firm. The stock began trading at a price of $33 per share, leading to approximately $1.2...

Continue Reading
Journey Medical Corporation's Emrosi Launch for Rosacea Relief

Updated Category News Views 215

Journey Medical Corporation Introduces Emrosi for Rosacea Treatment Journey Medical Corporation, a key player in the dermatological pharmaceutical industry, has recently launched Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules), designed for the effective treatment of rosacea. The product, featuring a unique formulation of 10 mg immediate release and...

Continue Reading